MedPath

BioLab 612 LLC

🇷🇺Russia
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:1

Trial Phases

1 Phases

Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (100.0%)

Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: Placebo
First Posted Date
2016-05-20
Last Posted Date
2016-07-20
Lead Sponsor
BioLab 612 LLC
Target Recruit Count
23
Registration Number
NCT02778763

Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer

Phase 2
Conditions
Colorectal Cancer
Interventions
Drug: Placebo
First Posted Date
2016-03-22
Last Posted Date
2017-02-09
Lead Sponsor
BioLab 612 LLC
Target Recruit Count
40
Registration Number
NCT02715882
Locations
🇷🇺

Federal State Budgetary Institution "State Scientific Center of Coloproctology named after A.N. Ryzhikh" Ministry of Health of the Russian Federation, Moscow, Russian Federation

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.